Stock UBX UNITY BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
1.625 USD +1.56% Intraday chart for Unity Biotechnology, Inc. +2.20% -15.80%
May. 14 Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 23 Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
AQ
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
AQ
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment
MT
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
AQ
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
CI
HC Wainwright Adjusts Unity Biotechnology Price Target to $8 From $10, Maintains Buy Rating
MT
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
AQ
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stocks Seen -2-
DJ
North American Morning Briefing : Markets Steady -2-
DJ
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
AQ
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss
CI
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
AQ
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME
CI
North American Morning Briefing : Stocks Futures -2-
DJ
Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325; Raises PT to $4 From $2
MT
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
AQ
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. UBX Stock
  4. News Unity Biotechnology, Inc.